Document:

Prepared by R.R. Donnelley Financial -- EX-10.17(a)

 Exhibit 10.17(a) 

CONFIDENTIAL 
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

TASK ORDER 
 MEDPACE
Task Order Number: 20 
 MEDPACE Project Number: CHS-0214-4 

This Task Order, dated November 8, 2013, is between Medpace, Inc. (“MEDPACE”), and Coherus Biosciences,
Inc. (“SPONSOR”). 
 RECITALS: 

WHEREAS, MEDPACE and SPONSOR have entered into that certain Master Services Agreement dated January 23, 2012 (the “Master
Services Agreement”); and 
 WHEREAS, pursuant to the Master Services Agreement, MEDPACE has agreed to perform certain Services
in accordance with Task Orders from time to time entered into by the Parties and SPONSOR and MEDPACE now desire to enter into such a Task Order; and 

WHEREAS, MEDPACE and SPONSOR desire to engage Medpace to perform certain initial services (“Services”) as set forth
hereinafter in connection with a A Double Blind, Randomized, Parallel Group, Active Control Study to Compare the Efficacy and Safety of CHS 0214 DP Versus Enbrel® in Subjects With Chronic
Plaque Psoriasis (PsO) (CHS-0214-04) (“Project”) , which is incorporated herein by reference; 
 NOW, THEREFORE, in
consideration of the mutual covenants contained herein, the Parties hereby agree as follows: 
  

	 	1.	Scope of Work: MEDPACE shall perform the initial services set forth in Appendix A, any other documents attached to and specifically referenced in this Task Order and any other initial services agreed to by both
Parties (“Initial Services”). The Initial Services must be conducted in compliance with the bid proposal provided by MEDPACE on October 7, 2013. The bid proposal is incorporated herein by reference and made a part of this Task Order.

  

	 	2.	Compensation: For performance of these Services, SPONSOR shall pay to MEDPACE according to terms set forth in Appendix A and the bid proposal for other initial activities requested. The Parties agree that [***].
After staff is assigned, [***]. 

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 1 of 15

	 	3.	Term. In addition to the termination rights provided in Section 6 of the MSA, upon execution by the Parties of a Task Order to provide the remaining Services for the Study, this Task Order #14 shall be
deemed terminated and superseded by such agreement. 

  

	 	4.	MSA. The provisions of the Master Services Agreement are hereby expressly incorporated by reference into and made a part of this Task Order. 

IN WITNESS WHEREOF, the Parties have hereunto signed this Task Order effective as of the day and year first written above. 

 

			
	MEDPACE, INC.
		
	Signature:	 	 /s/ John Wynne

	By:	 	 John Wynne

		 	(Print Name)
		 	Business Development Support
	Title:	 	 Executive Director

		
	Date:	 	Dec. 6 2013
	
	COHERUS BIOSCIENCES, INC.
		
	Signature:	 	 /s/ Dennis M. Lanfear

	By:	 	 Dennis M. Lanfear

		 	(Print Name)
	Title:	 	President & CEO
		
	 Date:
	 	12/5/2013

 List of Appendices: 

Appendix A: Scope of Work 
 Appendix B: Timeline

 Appendix C: Budget 

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 2 of 15

 Appendix D: Payment Schedule 

Appendix E: Transfer of Obligations 

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 3 of 15

 

 
  
 APPENDIX A: SCOPE OF WORK 

SERVICES: 
  

									
	 ITEM
	  	DESCRIPTION	 	  	 	 
		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  	 	[***]	  
	 [***]
	  				  			
		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  			

 1.1 PROJECT START-UP 
  

															
	 [***]
	  	[***]	 	  	[***]	  	ITEM	 	  	DESCRIPTION	 
	 [***]
	  				  		  	 	[***]	  	  			
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
	 [***]
	  				  		  	 	[***]|	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
	 [***]
	  				  		  	 	[***]	  	  			
	 [***]
	  				  		  	 	[***]	  	  			
		  	 	[***]	  	  		  	 	[***]	  	  			
	 [***]
	  				  		  	 	[***]	  	  			
	 [***]
	  				  		  	 	[***]	  	  	 	[***]	  

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 4 of 15

 

 
  
  

															
	 [***]
	  				  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
	 [***]
	  				  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  			
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  			
	 [***]
	  				  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  			
		  	 	[***]	  	  		  	 	[***]	  	  			
		  	 	[***]	  	  		  	 	[***]	  	  			
		  	 	[***]	  	  		  	 	[***]	  	  			

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 5 of 15

 

 
  
  

															
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  

 1.2 CLINICAL OPERATIONS 
  

															
	 [***]
	  	[***]	 	  	[***]	  	ITEM	 	  	DESCRIPTION	 
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
	 [***]
	  				  		  	 	[***]	  	  			
	 [***]
	  				  		  	 	[***]	  	  			
	 [***]
	  				  		  	 	[***]	  	  			
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
	 [***]
	  				  		  	 	[***]	  	  			
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  

 1.3 CLINICAL MONITORING 

 

															
	 [***]
	  	[***]	 	  	[***]	  	ITEM	 	  	DESCRIPTION	 
		  	 	[***]	  	  		  	 	[***]	  	  			
		  	 	[***]	  	  		  	 	[***]	  	  			
		  	 	[***]	  	  		  	 	[***]	  	  			
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  

 1.4 CLINICAL SAFETY 

 

															
	 [***]
	  	[***]	 	  	[***]	  	ITEM	 	  	DESCRIPTION	 
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  

 1.5 [***] SYSTEM 

 

									
	 [***]
	  	[***]	  	[***]	  	ITEM	  	DESCRIPTION

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 6 of 15

 

 
  
  

															
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  

 1.6 DATA MANAGEMENT 

 

															
	 [***]
	  	[***]	 	  	[***]	  	ITEM	 	  	DESCRIPTION	 
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
	 [***]
	  				  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  

 1.7 STATISTICAL ANALYSIS 

 

															
	 [***]
	  	[***]	 	  	[***]	  	ITEM	 	  	DESCRIPTION	 
		  	 	[***]	  	  		  	 	[***]	  	  	 	[***]	  

  
  

[***] Certain information in this document has been omitted and filed separately with the Securities and 

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 7 of 15

 

 
  
 APPENDIX B: TIMELINE 

1. Timelines 
  

					
	 TASK
	  	DATE	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 8 of 15

 

 
  
 APPENDIX C: BUDGET 

 

					
	 Service Category
	  	Direct Fees (USD)	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
		  	  
	  
	 
	 Total Direct Fees
	  	 	[***]	  
		  	  
	  
	 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 9 of 15

 

 
  
  

					
	Prefunded & Pass-Through Expenses	  	Fee	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
		  	  
	  
	 
	 Total Prefunded & Pass-Through Expenses
	  	 	[***]	  
		  	  
	  
	 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 10 of 15

 

 
  
 APPENDIX D: PAYMENT SCHEDULE 

 

																	
	Payment Schedule	 
	Project:	  	ETA304-CRO	 	  	Total Direct Fees	 	  	[***]	 	  	 	 
	 Sponsor:
	  	Coherus Biosciences, Inc.	 	  	 	 	  	 	 	  	 	 
	 Payment
	  	Payment/Description Type	 	  	Invoice Date	 	  	Amount	 	  	Percentage	 
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
		  	 	Total of All Payments:	  	  	 	[***]	  	  	 	100	% 

  

	* 	Invoicing for this milestone will occur on [***] 

 [***] of this Task Order [***] of the total Pre-funded
Expenses are due. [***]. SPONSOR shall pay such invoice within [***] of receipt. [***] received from SPONSOR, [***]. 
 Additionally, [***] of the total
estimated Pass-through Costs are due [***]. Pass-through Costs will be billed to SPONSOR [***]. 
 Pass-through Costs and Pre-funded Expenses 

Any sums quoted with respect to Pass-through Costs and Pre-funded Expenses [***]. While MEDPACE will [***]. Payments made to third parties are [***]. 

Pass-through Costs may include, but are not limited to, [***]. Costs associated with, [***] are as detailed in the table below. 

 
 [***] Certain information in this document has been omitted and filed
separately with the Securities and 
 Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 11 of 15

 

 
  
  

							
	 Item
	  	Cost*	 	Description	 
	 [***]
	  	[***]	 	 	[***]	  
	 [***]
	  	[***]	 	 	[***]	  
	 [***]
	  	[***]	 	 	[***]	  
	 [***]
	  	[***]	 	 	[***]	  
	 [***]
	  	[***]	 	 	[***]	  
	 [***]
	  	[***]	 	 	[***]	  
	 [***]
	  	[***]	 			
	 [***]
	  	[***]	 	 	[***]	  
	 [***]
	  	[***]	 	 	[***]	  
	 [***]
	  	[***]	 	 	[***]	  
	 [***]
	  	[***]	 	 	[***]	  
	 [***]
	  	[***]	 	 	[***]	  
	 [***]
	  	[***]	 	 	[***]	  
	 [***]
	  	[***]	 			
	 [***]
	  	[***]	 			
	 [***]
	  	[***]	 			
	 [***]
	  	[***]	 			
	 [***]
	  	[***]	 	 	[***]	  
	 [***]
	  	[***]	 	 	[***]	  

  

	* 	Currency is [***]. Costs are subject to change based on [***]. 

 MEDPACE will pass-through [***]. This will
include [***]. 
  

					
	 Item
	  	Cost	 	Description
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	

  

	* 	Currency is [***] 

  
 [***]
Certain information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 12 of 15

 

 
  
 Pre-funded Expenses 

Pre-funded Expenses may include, but are not limited to, [***]. Investigator fees are [***]. The investigator fee amount [***]. The laboratory fee amount
[***]. 
 Additional Costs 
 [***] 

All Direct Fees are [***]. All such changes [***]. After staff are assigned, [***]. 

Inflation 
 [***] 

Currency and Exchange Rate 
 The currency of this Task
Order is United States Dollars. 
 Medpace will invoice SPONSOR for Investigator payments [***]. The Direct Fees detailed in this Task Order were calculated
using the [***]. [***]. [***]. 
  

					
	COUNTRY	  	CURRENCY	 	1 USD (as of DD-MMM-2013) =
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]

  

[***] Certain information in this document has been omitted and filed separately with the Securities and 

Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 13 of 15

 

 
  
  

									
	 [***]
	  	 	[	***] 	 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 

 Applicable Taxes 
 All
Direct Fees, Pass-through Costs, and Pre-funded Expenses are quoted excluding any [***], which include but are not limited to [***], which may be payable to MEDPACE by SPONSOR. 

 
 [***] Certain information in this document has been omitted and filed
separately with the Securities and 
 Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 14 of 15

  
 

 
 APPENDIX E: TRANFER OF OBLIGATIONS 

CONFIDENTIAL 
 Directions: Complete a form for each
clinical study where Sponsor obligations have been transferred in accordance with 21 CFR Part 312, Subpart D (Responsibilities of Sponsors). Forward the completed form to Sponsor’s Regulatory Affairs Department for submission to the applicable
regulatory agencies. 
  

									
	Drug:	  	CHS-0214-DPVersus Enbrel	  	Study ID:	  	CHS-0214-04
		
	Study Title:	  	A Double Blind, Randomized, Parallel Group, Active Control Study to Compare the Efficacy and Safety of CHS 0214 DP Versus Enbrel® in Subjects With Chronic Plaque
Psoriasis (PsO) (CHS-0214-04)
		
	CRO Name:	  	Medpace
		
	CRO Address:	  	5375 Medpace Way, Cincinnati, Ohio 45227
	
	 OBLIGATIONS TRANSFERRED TO MEDPACE: þ THE APPROPRIATE BOX(ES).
  

 ̈ All obligations in 21 CFR 312, Subpart D (Responsibilities of Sponsors) have been
transferred to Medpace.
  

x The following obligations have been transferred to Medpace:

 
 Sec. 312.32: IND Safety Reports 

	 ̈	Promptly review safety information. 

  

	x	Notify all participating investigators in a written IND safety report of any AE associated with the drug that is both serious and unexpected. 

 

	 ̈	Notify the FDA in a written IND safety report of any AE associated with the drug that is both serious and unexpected. 

Sec. 312.53: Selecting investigators and monitors 

	x	(a) Select qualified investigators 

  

	x	(b) Control investigational drug shipment 

  

	x	(c) Obtain information from investigators 

  

	 	x	(1) Signed Form FDA-1572 

  

	 	x	(2) CV or other qualification statement 

  

	 	x	(3) Clinical protocol outline 

  

	 	x	(4) Financial disclosure information 

  

	x	(d) Select qualified monitors 

 Sec. 312.54: Emergency research 

	 ̈	(a) Monitor the progress of all studies involving an exception from informed consent. 

  

	x	(b) Monitor such studies to identify when an IRB determines that it can’t approve the research. 

 Sec.
312.55: Informing investigators 

	x	(a) Provide sites with the current Inv. Brochure. 

  

	x	(b) Inform investigators of new observations on the drug, particularly with respect to AEs and safe use. 

Sec. 312.56: Review of ongoing investigations 

	 ̈	(a) Monitor the progress of all IND studies. 

  

	x	(b) Secure compliance from noncompliant investigators or discontinue drug shipments and end the investigator’s participation in the study. 

 

	x	(c) Review and evaluate the safety and efficacy results as it is obtained from the investigator. 

  

	x	(d) Discontinue use of the investigational drug if it is determined to present an unreasonable and significant risk to subjects, notify all IRBs and investigators, and assure the return or alternate disposition of the
drug from the investigators. 

 Sec. 312.57: Record keeping and record retention 

	x	(a) Maintain adequate records showing investigational drug receipt, shipment, or other disposition. 

  

	x	(b) Maintain complete and accurate records showing any financial interests of the investigator subject to 21 CFR 54. 

  

	x	(c) Retain the records and reports required by the regulations for 2 years after the marketing application is approved, or if not approved, until 2 years after investigational drug shipment is discontinued and FDA has
been notified. 

  

	 ̈	(d) Retain reserve samples of any test article and reference standard identified and used in bioequivalence or bioavailability studies. 

Sec. 312.58: Inspection of sponsor’s records and reports 

	x	(a) Permit FDA personnel to have access to and copy and verify any records and reports related to the clinical investigation. 

  

	x	(b) Permit DEA personnel to have access to and copy records related to the shipment, delivery, receipt and disposition of any investigational controlled substance. Assure adequate storage precautions are taken for
investigational new drug substances listed in any schedule of the Controlled Substances Act. 

 Sec. 312.59: Disposition of unused supply of
investigational drug 

	x	Assure the return (or alternate disposition) of all unused supplies of the investigational drug from each discontinued/terminated investigator; maintain written records of any disposition of the investigational drug.

  

	(a)	Other 

	x	Please describe any other applicable transfers below: 

 Medpace Inc. will contract directly with the clinical
trial investigators and sites, ensure the sites are trained on the protocol and study procedures, and carry out the study protocol as written. The study sites will enroll and manage subjects per study protocol, enter correct and accurate subject
information into the clinical trial electronic case report form system, retain subject information and study drug supply information as noted above, and manage study blood samples as outlined in the study protocol. Site Investigator’s are
responsible for notifying the Institutional review board (IRB) of research activities and following IRB regulations of GCP. The site investigators are responsible for notifying Medpace Drug Safety, and the sponsor of safety information including the
prompt notification of any subject serious adverse events. The investigators are also responsible to promptly notify the IRB of any serious adverse event per GCP and CFR.

 

  

  

			
	

	  	 Medpace Task Order 20

Coherus Biosciences, Inc.
 CHS-0214-4
Start up
 Page 15 of 15Prepared by R.R. Donnelley Financial -- EX-10.17(b)

 Exhibit 10.17(b) 

 

CONFIDENTIAL 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 AMENDMENT #1 TO TASK ORDER #20

 COHERUS Project Number: CHS-0214-04 

MEDPACE Project Number: ETA304 

This Amendment #1 (“Amendment #1”) to Task Order #20 effective as of November 8, 2013 (“Task Order”), is by and
between Coherus Biosciences, Inc., a Delaware corporation with its principal place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, CA 94065 (“Sponsor”), and Medpace, Inc., with its principal place of
business at 5375 Medpace Way, Cincinnati, Ohio 45227 (“Medpace”). This Amendment #1 shall be effective April 23, 2014. 

WITNESSETH: 

WHEREAS, the Parties have entered into Task Order pursuant and subject to the terms of the Master Service Agreement dated
January 23, 2012, (the “Agreement”); and 
 WHEREAS, the Parties desire to amend Task Order in connection with A Phase
3, Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Chronic Plaque Psoriasis (PsO) to add Medpace
Reference Laboratories (“MRL”) Services and Fees, which includes [***] vendor services. 
 NOW, THEREFORE, in consideration
of the mutual covenants contained herein, the Parties hereby agree as follows to the revised Scope of Work. 
  

	 	1.	Appendix A: Scope of Work, attached to Task Order #20 is hereby amended to include MRL and [***] start-up services included in Appendix F attached to this Amendment #1. 

 

	 	2.	Appendix C: Budget, attached to Task Order #20 is hereby amended to include MRL and [***] fees included in Appendix F attached to this Amendment #1. 

 

	 	3.	As a result of the increase in the Budget, Appendix D: Payment Schedule, attached to Task Order #20 is hereby amended to increase the [***] upfront payment of Pass-through Costs by [***], which increase is due upon
execution of this Amendment #1. 

  

			
	

	  	 Medpace Amendment #1 to Task Order #20

Coherus Biosciences, Inc.
 CHS-0214-04 /
ETA 304
  Page
 1

 The total amount payable by Sponsor to Medpace under this Amendment #1 for Medpace Direct Fees, Pass-through
Expenses, and Pre-funded Expenses shall not exceed the amount of [***] without prior written consent of both parties. The total value of Task Order and all subsequent amendments is now [***]. 

 

																	
	 	  	Direct Fees	 	 	Pass Through Costs	 	 	Pre-funded Expenses	 	 	TOTAL	 
					
	 Task Order #20
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
					
	 Amendment #1
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
					
	 TOTAL
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 

 All other provisions of the Agreement and Task Order shall remain unchanged and in effect. 

IN WITNESS WHEREOF, the Parties have hereunto signed this Amendment #1 to Task Order in their official capacities which shall be effective on the day
and year listed above. 
  

			
	MEDPACE, INC.
		
	Signature:	 	/s/ John Wynne

			
		
	By:	 	John Wynne
		 	(Print Name)

			
		
	Title:	 	Vice President Commercial Operations

  

			
	COHERUS BIOSCIENCES, INC.
		
	Signature:	 	/s/ Dennis M. Lanfear

			
		
	By:	 	Dennis M. Lanfear
		 	(Print Name)

			
		
	Title:	 	Chief Executive Officer

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 
  

			
	

	  	 Medpace Amendment #1 to Task Order #20

Coherus Biosciences, Inc.
 CHS-0214-04 /
ETA 304
  Page
 2

 APPENDIX F: MRL AND [***] Services and Budget 

 

					
	Sponsor:	    	Coherus Biosciences	  	23-Apr-14
	Protocol:	    	CHS-0214-04 Start-up	  	

  
  

							
	 [***]
	  		  	 	[	***] 
		  	[***]	  	 	[	***] 
		  	[***]	  	 	[	***] 
	 Total Medpace Reference Laboratories Fees
	  		  	 	[	***] 

  

											
	Medpace Reference Laboratories Fee Estimate
	 Sponsor: Coherus Biosciences

Protocol: CHS-0214-04 Start-up
	  	

[***]
			
	 	  	 	  	Number of Analyses Per Visit
						
	 	  	Unit Cost	  	Screening
W-4	  	Total
Number
of Units	  	Cost	  	Subtotal
	Laboratory Tests	  	 	  	 	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
						
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
						
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	Laboratory/Support
Services	  	 	  	 	  	[***]
	[***]	  	 	  	 	  	 	  	 
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	[***]	  		  		  		  	
	[***]	  	[***]	  		  		  		  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  		  		  		  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	 	  	 	  	 	  	 
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	Total Medpace Reference Laboratory Fees	  	 	  	 	  	[***]

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 
  

			
	

	  	 Medpace Amendment #1 to Task Order #20

Coherus Biosciences, Inc.
 CHS-0214-04 /
ETA 304
  Page
 3

					
	Medpace Reference Laboratories Pass Through Estimate
	 Sponsor: Coherus Biosciences

Protocol: CHS-0214-04 Start-up
	  		  	
	 	  	Total Cost	  	Subtotal
	Pass Through Estimates	  	 	  	[***]
	 [***]
	  	 	  	 
	[***]	  	[***]	  	
	[***]	  	[***]	  	
	Total Estimated Medpace Reference Laboratory Pass-Through Fees	  		  	[***]

 Transportation Costs 
  

																									
	Country	  	Sites	  	Number
Screened	  	Number
Ambient /
Refrigerate
shipments	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	 
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	Total	  	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]	  	
		  		  		  		  		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]	  	[***]

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 
  

			
	

	  	 Medpace Amendment #1 to Task Order #20

Coherus Biosciences, Inc.
 CHS-0214-04 /
ETA 304
  Page
 4

 [***] 

[***] 
 CONFIDENTIAL 

 

					
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 

  

																									
	 Date, Version: [***]

Prepared by [***]: [***]

Prepared for [***]: [***]

Client & Protocol: Medpace – CHS-0214-04

Phase: III

[***]: [***]

[***]: [***]

[***]: [***]

[***]: [***]

[***]: [***]
	  	 
 	Unit 
Price [***]	 
  	 	 	[***]	  	 	 	[***]	  	 	 	[***]	  	 	 	[***]	  	 	 	Total [***]	  
	 [***]: [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 			
	 [***]: [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 			
	 [***]: [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 			
	 [***]: [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 			
	 [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
	 [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
	 [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
	 [***]
	  				 				 				 				 				 	 	[	***] 
	 [***]
	  				 				 				 				 				 			
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  				 				 				 				 				 	 	[	***] 
	 [***]
	  				 				 				 				 				 	 	[	***] 
	 [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
	 Total [***]
	  				 				 				 				 				 	 	[	***] 

 “[***]. 
 Notes: 

	1.	[***] 

	2.	[***] 

	3.	[***] 

	4.	[***] 

	5.	[***] 

	6.	[***] 

	7.	[***] 

	8.	[***] 

	9.	[***] 

	10.	[***] 

	11.	[***] 

 ASSUMPTIONS: 

	1.	[***] 

	2.	[***] 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 [***] Estimated Budget 

CONFIDENTIAL 
 [***]: [***]

  

																									
	 [***]
	  	 	[	***] 	 				 				 				 				 			
	 [***]
	  	 	[	***] 	 				 				 				 				 			
	 [***]

Date, Version: [***]

Client Protocol: Medpace – CHS-0214-04

[***]: [***]

[***]: [***]

[***]: [***]

[***]: [***]
	  	 
 	Unit Price
[***]	  
  	 	 	[***]	  	 	 	[***]	  	 	 	[***]	  	 	 	[***]	  	 	 	Total [***]	  
	 [***]
	  				 				 				 				 				 			
	 [***]
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
	 [***]
	  				 				 				 				 				 	 	[	***] 
	 [***]
	  				 				 				 				 				 			
	 [***]
	  	 	[	***] 	 				 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 				 				 				 				 	 	[	***] 
	 [***]
	  				 				 				 				 				 	 	[	***] 
	 [***]
	  				 				 				 				 				 			
	 [***]
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
	 [***]
	  	 	[	***] 	 				 				 				 	 	[	***] 	 	 	[	***] 
	 [***]
	  				 				 				 				 				 	 	[	***] 
	 Total [***]
	  				 				 				 				 				 	 	[	***] 

 [***] Notes: 

	1.	[***] 

 Additional [***] Clinical Trials Services 

 

					
	 [***]
	  		  	[***]
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	

  

													
	 [***]
	  	Unit Price
 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	Total [***]
	 [***]
	  		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 Total [***]
	 		 		 	[***]

 [***] Notes: 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 [***] Estimated Budget 

CONFIDENTIAL 
 [***]: [***]

  

															
	 [***]
	  	[***]	 		 		 		 		 		 	
	 [***]
	  	[***]	 		 		 		 		 		 	
	 [***]

Date, Version: [***]

Client Protocol: Medpace – CHS-0214-04

[***]: [***]

[***]: [***]

[***]: [***]

[***]: [***]
	  	Unit Price
[***]	 	Unit Price
[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	Total [***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  		 		 		 		 		 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  		 		 		 		 		 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  		 		 		 		 		 		 	[***]
	 Total [***]
	  		 		 		 		 		 		 	[***]

 [***] Notes: 

	1.	[***] 

 Additional [***] Clinical Trials Services 

 

					
	 [***]
	  		  	[***]
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	

  

															
	[***]	  	Unit Price
[***]	 	Unit Price
[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	Total [***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 Total [***]
	 		 		 	[***]

 [***] Notes: 
 [***]

	1.	[***] 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 [***] Estimated Budget 

CONFIDENTIAL 
 [***]: [***]

  

															
	 [***]
	  	[***]	  		  		  		  		  		  	
	 [***]
	  	[***]	  		  		  		  		  		  	
	 [***]
 Date, Version: [***]

Client Protocol: Medpace – CHS-0214-04

[***]: [***]

[***]: [***]

[***]: [***]

[***]: [***]
	  	Unit Price
[***]	  	Unit Price
[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	Total [***]
	 [***]
	  		  		  		  		  		  		  	
	 [***]
	  	See [***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  		  		  		  		  		  		  	[***]
	 [***]
	  		  		  		  		  		  		  	
	[***]	  		  		  		  		  		  		  	[***]
	 [***]
	  		  		  		  		  		  		  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  		  		  		  		  		  		  	[***]
	Total [***]	  		  		  		  		  		  		  	[***]

 [***] Notes: 

	1.	[***] 

 Additional [***] Clinical Trials Services 

 

					
	 [***]
	  		  	[***]
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	

  

																	
	[***]	  	[***]	 	Unit
Price	 	Unit
Price
[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	Total [***]
	 [***]
	  		 		 		 		 		 	
	 [***]
	  	[***]	 		 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 		 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 		 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***][***]
	 [***]
	  		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 Total [***]
	 	[***]

 [***] Notes: 
 [***]

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 

 CONFIDENTIAL 

[***] 
  

															
		  		  		  		  	[***]	  		  	[***]	  	
	I	  	[***]	  		  		  		  		  		  	
								
		  	[***]	  		  		  		  		  		  	
								
		  	 [***]
	  		  	[***]	  		  	[***]	  		  	[***]
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
								
	II	  	[***]	  		  		  		  		  		  	
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
								
	III.	  	[***]	  		  		  		  		  		  	
								
		  	[***]	  		  		  		  		  		  	
		  	[***]	  		  		  		  		  		  	
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	 [***]
	  		  		  		  		  		  	
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	 [***]
	  		  		  		  		  		  	
		  	 [***]
	  		  		  		  		  		  	
								
		  	[***]	  	[***]	  		  		  		  		  	
		  	 [***]
	  	[***]	  		  		  		  		  	
		  	 [***]
	  		  		  		  		  		  	
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  		  		  		  		  		  		  	

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]